Compared side by side
Melanotan II vs setmelanotide: how they differ
The short answer
Both are melanocortin receptor agonists modelled on α-MSH: melanotan II is broad-spectrum, acting on MC1R, MC3R, MC4R and MC5R, so it tans the skin, raises libido and can reduce appetite, while setmelanotide is aimed at the MC4 receptor of the brain’s hunger pathway. Setmelanotide is FDA-approved, as Imcivree, a daily shot for rare kinds of obesity where that pathway is broken, and its label says it is not expected to work in common obesity; melanotan II has no FDA-approved product. Both darken the skin: setmelanotide through a weaker action on the MC1 receptor of pigment cells, and melanotan II by design, darkening all pigmented skin, freckles and moles included.
Side by side
| Compared | Melanotan II | Setmelanotide |
|---|---|---|
| Category | Sexual health | Metabolic & GLP-1 |
| Also known as | MT-2, MT2, Melanotan 2 | Imcivree, RM-493, BIM-22493 |
| What it is | A broad-spectrum melanocortin agonist originally developed for sunless tanning. | A daily shot (Imcivree) for rare kinds of obesity in which the brain's fullness signal is broken: after damage to the hypothalamus, in Bardet-Biedl syndrome, or with a POMC, PCSK1 or LEPR gene variant. |
| How it works | Melanocortin receptor agonist (MC1R, MC3R, MC4R, MC5R). Stimulates melanogenesis (skin tanning), increases libido via CNS pathways, and can reduce appetite (a side effect in one small trial; the MC4R appetite mechanism comes from rodent work). Structurally similar to alpha-MSH. | A melanocortin-4 (MC4) receptor agonist: an 8-amino-acid ring-shaped peptide built on α-MSH, the body's own signal on the brain's hunger and satiety pathway. Where that pathway is broken upstream of the MC4 receptor (a hypothalamic injury or tumour, Bardet-Biedl syndrome, or a POMC, PCSK1 or LEPR gene variant), it is thought to restore the signal, lowering hunger and food intake and raising energy use. It also acts, about 20-fold more weakly, on the MC1 receptor of pigment cells, which is why the skin darkens. FDA-approved in 2020; acquired hypothalamic obesity was added in March 2026. The label says it is not expected to work in common (polygenic) obesity. |
| Commonly reported | Nausea and facial flushing after the first doses, easing with continued use; a fast, deep tan with freckles and moles visibly darkening; and spontaneous erections, frequent yawning and reduced appetite. Monitor moles carefully — it darkens all pigmented skin, and FDA cites melanoma reports. | Less hunger within weeks, skin and moles darkening, and nausea at the start. FDA-approved since 2020. |
| Studied range | Research range: 250–500 mcg. Studied in research — not a recommendation. | FDA label: 0.5–3 mg, starting dose 0.5 mg. |
| How often | Loading: 250mcg daily for 1-2 weeks. Maintenance: 250-500mcg 2-3x/week or as needed. | Daily SubQ |
| Half-life | Unknown in humans | ~11 hours (FDA label) |
| Route | SubQ injection | SubQ injection |
| Typical run | Loading phase until desired tan achieved, then reduce to maintenance. Sun or UV exposure enhances tanning effect. | FDA-approved for long-term use ("reduce excess body weight and maintain weight reduction long term"); its trials ran 52 to 66 weeks. In the gene-variant trials, weight came back during a 4-week placebo withdrawal and fell again on restarting. |
| Evidence | Emerging: primarily preclinical / limited human data | Established: clinical trials or FDA-approved use exists |
| Common side effects | Nausea, facial flushing, spontaneous erections, fatigue, darkening of moles/freckles, yawning | Skin darkening, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, low mood, spontaneous erections |
- Category
- Melanotan IISexual health
- SetmelanotideMetabolic & GLP-1
- Also known as
- Melanotan IIMT-2, MT2, Melanotan 2
- SetmelanotideImcivree, RM-493, BIM-22493
- What it is
- Melanotan IIA broad-spectrum melanocortin agonist originally developed for sunless tanning.
- SetmelanotideA daily shot (Imcivree) for rare kinds of obesity in which the brain's fullness signal is broken: after damage to the hypothalamus, in Bardet-Biedl syndrome, or with a POMC, PCSK1 or LEPR gene variant.
- How it works
- Melanotan IIMelanocortin receptor agonist (MC1R, MC3R, MC4R, MC5R). Stimulates melanogenesis (skin tanning), increases libido via CNS pathways, and can reduce appetite (a side effect in one small trial; the MC4R appetite mechanism comes from rodent work). Structurally similar to alpha-MSH.
- SetmelanotideA melanocortin-4 (MC4) receptor agonist: an 8-amino-acid ring-shaped peptide built on α-MSH, the body's own signal on the brain's hunger and satiety pathway. Where that pathway is broken upstream of the MC4 receptor (a hypothalamic injury or tumour, Bardet-Biedl syndrome, or a POMC, PCSK1 or LEPR gene variant), it is thought to restore the signal, lowering hunger and food intake and raising energy use. It also acts, about 20-fold more weakly, on the MC1 receptor of pigment cells, which is why the skin darkens. FDA-approved in 2020; acquired hypothalamic obesity was added in March 2026. The label says it is not expected to work in common (polygenic) obesity.
- Commonly reported
- Melanotan IINausea and facial flushing after the first doses, easing with continued use; a fast, deep tan with freckles and moles visibly darkening; and spontaneous erections, frequent yawning and reduced appetite. Monitor moles carefully — it darkens all pigmented skin, and FDA cites melanoma reports.
- SetmelanotideLess hunger within weeks, skin and moles darkening, and nausea at the start. FDA-approved since 2020.
- Studied range
- Melanotan IIResearch range: 250–500 mcg. Studied in research — not a recommendation.
- SetmelanotideFDA label: 0.5–3 mg, starting dose 0.5 mg.
- How often
- Melanotan IILoading: 250mcg daily for 1-2 weeks. Maintenance: 250-500mcg 2-3x/week or as needed.
- SetmelanotideDaily SubQ
- Half-life
- Melanotan IIUnknown in humans
- Setmelanotide~11 hours (FDA label)
- Route
- Melanotan IISubQ injection
- SetmelanotideSubQ injection
- Typical run
- Melanotan IILoading phase until desired tan achieved, then reduce to maintenance. Sun or UV exposure enhances tanning effect.
- SetmelanotideFDA-approved for long-term use ("reduce excess body weight and maintain weight reduction long term"); its trials ran 52 to 66 weeks. In the gene-variant trials, weight came back during a 4-week placebo withdrawal and fell again on restarting.
- Evidence
- Melanotan IIEmerging: primarily preclinical / limited human data
- SetmelanotideEstablished: clinical trials or FDA-approved use exists
- Common side effects
- Melanotan IINausea, facial flushing, spontaneous erections, fatigue, darkening of moles/freckles, yawning
- SetmelanotideSkin darkening, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, low mood, spontaneous erections
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Melanotan II
- Day 1–3 Start low — your body needs to adjust
- Day 3–7 Melanocytes are waking up
- Day 7–14 The tan is developing
- Day 14–28 Transition to maintenance
Setmelanotide
- Day 1–14 · 0.5 mg The 0.5 mg start
- Day 1–14 · 2 mg The 2 mg start
- Day 14–90 Why the skin darkens
- Day 15–365 · 3 mg 3 mg, the maintenance dose
Questions people ask
How long do Melanotan II and setmelanotide last?
The half-life of Melanotan II is unknown in humans. The half-life of setmelanotide is ~11 hours (FDA label).
How often are Melanotan II and setmelanotide taken?
Melanotan II: loading: 250mcg daily for 1-2 weeks. Maintenance: 250-500mcg 2-3x/week or as needed. Route: SubQ injection. Setmelanotide: daily SubQ. Route: SubQ injection.
How are Melanotan II and setmelanotide dosed in research?
The research range for Melanotan II is 250–500 mcg. Studied in research — not a recommendation. The FDA label range for setmelanotide is 0.5–3 mg, with a 0.5 mg starting dose.
What are the common side effects of Melanotan II and setmelanotide?
For Melanotan II, the library lists: nausea, facial flushing, spontaneous erections, fatigue, darkening of moles/freckles, yawning. For setmelanotide: skin darkening, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, low mood, spontaneous erections.